AstraZeneca Pays CEO Soriot Nearly $15M After 2018's Return to Growth. Will Investors Push Back? - Pharma News -BoardProspects

AstraZeneca Pays CEO Soriot Nearly $15M After 2018's Return to Growth. Will Investors Push Back?

Pharma News Mar 5 2019 BoardNews

AstraZeneca CEO Pascal Soriot earned £11.36 million in total pay last year, a 9% increase over 2017. (AstraZeneca) In the past, AstraZeneca's investors have hit out at the company for executive compensation they deemed over-the-top. And they may have something to say about CEO Pascal Soriot's £11.36 million ($14.93 million) in total pay last year, a 9% jump from 2017...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- TaskRabbit CEO Steps Down, Making Silicon Valley’s Diversity Outlook Bleak also categorized in BoardNews
- Actavis Chairman Joins Zoetis Board Under Deal With Activist Investor Ackman also published in Pharma News
- AstraZeneca Investors Press Exec-Comp Chair to Tie Pay to Pfizer Bid also published in Pharma News
- Corporate Boards: Shifting From Aging Men To New Generation Of Women? also categorized in BoardNews
- Board of Directors Compensation on the Rise, but less of it is cash also mentions stock options
- CEOs and Executives of Companies Filing for Bankruptcy Make Millions also categorized in BoardNews
- CEOs Are Cutting Their Own Salaries In Response To The Coronavirus also categorized in BoardNews
- AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises also published in Pharma News
- Germany's Corporate Governance Problem also categorized in BoardNews
- Disney Furloughs 100,000 Workers While Top Executives Will Still Get Big Bonuses also categorized in BoardNews

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Topics Mentioned